Schuijt Tim J, Lankelma Jacqueline M, Scicluna Brendon P, de Sousa e Melo Felipe, Roelofs Joris J T H, de Boer J Daan, Hoogendijk Arjan J, de Beer Regina, de Vos Alex, Belzer Clara, de Vos Willem M, van der Poll Tom, Wiersinga W Joost
Center for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Department of Medicine, Division of Infectious Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Department of Clinical Chemistry, Hematology and Immunology, Diakonessenhuis Utrecht, The Netherlands.
Center for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Gut. 2016 Apr;65(4):575-83. doi: 10.1136/gutjnl-2015-309728. Epub 2015 Oct 28.
Pneumonia accounts for more deaths than any other infectious disease worldwide. The intestinal microbiota supports local mucosal immunity and is increasingly recognised as an important modulator of the systemic immune system. The precise role of the gut microbiota in bacterial pneumonia, however, is unknown. Here, we investigate the function of the gut microbiota in the host defence against Streptococcus pneumoniae infections.
We depleted the gut microbiota in C57BL/6 mice and subsequently infected them intranasally with S. pneumoniae. We then performed survival and faecal microbiota transplantation (FMT) experiments and measured parameters of inflammation and alveolar macrophage whole-genome responses.
We found that the gut microbiota protects the host during pneumococcal pneumonia, as reflected by increased bacterial dissemination, inflammation, organ damage and mortality in microbiota-depleted mice compared with controls. FMT in gut microbiota-depleted mice led to a normalisation of pulmonary bacterial counts and tumour necrosis factor-α and interleukin-10 levels 6 h after pneumococcal infection. Whole-genome mapping of alveolar macrophages showed upregulation of metabolic pathways in the absence of a healthy gut microbiota. This upregulation correlated with an altered cellular responsiveness, reflected by a reduced responsiveness to lipopolysaccharide and lipoteichoic acid. Compared with controls, alveolar macrophages derived from gut microbiota-depleted mice showed a diminished capacity to phagocytose S. pneumoniae.
This study identifies the intestinal microbiota as a protective mediator during pneumococcal pneumonia. The gut microbiota enhances primary alveolar macrophage function. Novel therapeutic strategies could exploit the gut-lung axis in bacterial infections.
在全球范围内,肺炎导致的死亡人数超过其他任何传染病。肠道微生物群支持局部黏膜免疫,并且越来越被认为是全身免疫系统的重要调节因子。然而,肠道微生物群在细菌性肺炎中的确切作用尚不清楚。在此,我们研究肠道微生物群在宿主抵御肺炎链球菌感染中的功能。
我们使C57BL/6小鼠的肠道微生物群减少,随后经鼻用肺炎链球菌感染它们。然后我们进行了生存和粪便微生物群移植(FMT)实验,并测量了炎症参数和肺泡巨噬细胞全基因组反应。
我们发现,肠道微生物群在肺炎球菌肺炎期间保护宿主,这表现为与对照组相比,微生物群减少的小鼠细菌播散增加、炎症加剧、器官损伤和死亡率上升。在肠道微生物群减少的小鼠中进行FMT导致肺炎球菌感染后6小时肺部细菌计数、肿瘤坏死因子-α和白细胞介素-10水平恢复正常。肺泡巨噬细胞的全基因组图谱显示,在缺乏健康肠道微生物群的情况下代谢途径上调。这种上调与细胞反应性改变相关,表现为对脂多糖和脂磷壁酸的反应性降低。与对照组相比,源自肠道微生物群减少的小鼠的肺泡巨噬细胞吞噬肺炎链球菌的能力减弱。
本研究确定肠道微生物群是肺炎球菌肺炎期间的一种保护性介质。肠道微生物群增强原发性肺泡巨噬细胞功能。新的治疗策略可以利用肠道-肺轴来治疗细菌感染。